PR89334

SEOUL, South Korea, May 7, 2021 /PRNewswire=KYODO JBN/ --

RNA therapeutics, a breakthrough for major modern diseases such as Corona 19,

orphan diseases, and chronic diseases

Nexturn Bio Inc. completed its first investment review on RosVivo Therapeutics

Inc., a new miRNA drug company in the U.S.

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140),

has selected its first technological investment target to expand its new bio

business. Nexturn Bio announced that it has secured a 50% stake in RosVivo

Therapeutics, Inc. as its final investment destination under support from its

parent company Nexturn Bioscience Co., Ltd. RosVivo, planned to receive

investment from Nexturn Bio Inc., is an R&D company for miRNA (MicroRNA) new

drugs in Nevada.

While the development of RNA vaccines has been spotlighted since the Corona-19

outbreak, RSVI-301, a new drug pipeline of RosVivo targeting diabetes, also

uses miRNA (micro RNA). Consisting of 20–24 nucleotide, miRNA is known as a

"small cleaner" in the body that naturally regulates metabolic processes of

genes and proteins. Since these miRNA treatments inject human-derived genetic

materials, they are expected to be of greater value in stability than

conventional mRNA treatments using external genetic materials like viruses.

In particular, miR-10-5p study, underlying study of the new drug development,

enables the researchers to observe the world's first pancreatic beta cell

regeneration. Nexturn Bio Inc. and RosVivo Therapeutics, Inc. said they will

appoint Scientific Advisory Board (SAB) for thorough verification as it is

important precedent for diabetes research. The advisors will be staffed at

several major national Hospitals, such as Stanford University of Medicine, to

support professional advice throughout the drug development.

Beta cells have been regenerated as much as normal mice (first) after

miR-10a-5p injection in diabetic mice (third), induced by high-fat carbohydrate

diet.

Nexturn Bio Inc. plans to catch both "innovation" and "marketability" through

RosVivo's new miRNA drug. It has been reported that CEO Song Myung-Seok  

participated to discover candidates while establishing a subsidiary. "RosVivo

is the first official investment of Nexturn Bio, and RSVI-301 of RosVivo will

be an innovative opportunity to open a new era of medicine after mRNA and

challenge the complete cure of diabetes," said the CEO.

SOURCE NEXTURN Bio Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=390559

   Caption: miR-10-5p performs as a key factor in GI dysmotility and Diabetes via the

KLF11-KIT pathway